About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, January 14th, 2015

The QualityStocks
Daily Stock List

graphic
graphic

DigiPath Corp. (DIGP)

Otcstockexchange, Whisper from Wall Street, SmallCapStockPlays, Wallstreetbuzz, SmallCapVoice, DSR News, Investor News Source, StockRockandRoll, PennyStockLocks.com, TheMicrocapNews, AddictivePennyStocks, PricelessPennyStocks, PennyStockRumors.net, and Real Pennies reported earlier on DigiPath Corp. (DIGP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Las Vegas, Nevada based DigiPath Corp. is a digital pathology solution provider that is rapidly expanding into cannabis testing and related services. The National Marijuana News (TNMNews) is DigiPath’s unbiased cannabis news site and talk radio show. It centers on the political, economic, medicinal, as well as cultural dimensions of the fast developing medicinal and recreational marijuana industry. In November 2014, DigiPath announced that it received approval from the State of Nevada for its DigiPath Labs subsidiary to open and operate a cannabis testing laboratory at 6450 Cameron Street, Suite 113, in Las Vegas, Nevada. The expectation is that the lab will open its doors to customers in early 2015. DigiPath lists on the OTC Market Group’s OTCQB.

The Company develops and markets accurate and affordable human and animal digital pathology solutions. It is expanding into the botanical, nutraceutical, and cannabis industries with industry-leading testing, education, and training services. DigiPath’s systems enable entities to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath has a digital pathology portfolio. PathScope™ is its’ whole slide imaging system.

PathScope™ delivers high-quality real-time images, and integrates smoothly with third-party software. PathLive™ is the Company’s telepathology system. It delivers high-quality images in real time. PathReview™ is DigiPath’s proprietary web viewer and image server management system for whole digital slide images.

PathConsult™ is its’ end-to-end digital pathology solution. PathConsult™ enables remote consultation and second opinions, strong reporting and workflow management for histotechnicians, pathologists and administrators. In addition, DigiPath’s digital pathology solutions include PathCloud™, PathTrade™, PathStore™, and PathGuarentee™.

The Company’s line of advanced digital pathology and advisory solutions include marketing, product development, sales, outreach, operations, customer service, regulatory, and financial management services for the healthcare industry. DigiPath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using Food and Drug Administration (FDA)-compliant laboratory equipment and processes to ensure product and patient safety and effectiveness.

Moreover, DigiPath Education and Training is developing a two-day seminar and a modularized six-week, instructor-facilitated online course. This is for people who wish to learn more about cannabis or who are seeking employment in the industry.

DigiPath Corp. (DIGP), closed Wednesday's trading session at $0.0276, down 16.11%, on 391,093 volume with 8 trades. The average volume for the last 60 days is 257,828 and the stock's 52-week low/high is $0.0236/$6.00.

BIO-key International, Inc. (BKYI)

SmallCap Voice, PennyStocks24, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, StockOnion, SecretStockPromo, Penny Pick Finders, FeedBlitz, and HotStockChat reported earlier on BIO-key International, Inc. (BKYI), and we report on the Company today, here at the QualityStocks Daily Newsletter.

BIO-key International, Inc. is a leader in fingerprint biometric identification technologies, secure cloud- and device-based mobile credentialing and identity verification solutions. The Company develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. BIO-key International is headquartered in Wall, New Jersey. The Company’s shares trade on the OTCQB.

The Company’s solutions are used in local embedded original equipment manufacturer (OEM) products and some of the world's largest identification deployments to improve security, guarantee identity, and help reduce identity theft. BIO-key's technology is offered directly or by market leading partners around the world.

BIO-key International helps customers reduce risk and protect the value of their services and assets, while minimizing the continuing costs for Access Control and Identity Management. The Company’s biometric finger identification technology is award winning, high performance, scalable, cost-effective, and easy-to-deploy. It accurately identifies and authenticates users of wireless and enterprise applications.

The Company’s products include SideSwipe® Mini Fingerprint Reader, Web-key®, VST-Vector Segment Technology™, ID Director for Allscripts HER, ID Director for EpicCare, ID Director for CA SiteMinder, ID Director for IBM ISAM for Web, BIO-key BSP for IBM ESSO, BIO-key BSP for Oracle Access Manager, and ID Director for Windows.

Yesterday, BIO-key International reported it generated revenue in the fourth quarter and full 2014 fiscal year from advanced fingerprint authentication solutions within its OEM & Mobility business segment. The OEM business, including Mobility, generated more than $500K in revenue in the fourth quarter FY 2014 and almost $2M for the full fiscal year.

BIO-key International entered collaborative development efforts with Advanced Micro Devices (AMD) and Trustonic, following the launch of its Strategic Development Agreement with InterDigital Corporation (IDCC). BIO-key expanded the capabilities of its NIST-validated Vector Segment Technology algorithm to include full size, small area and swipe sensors. It licensed the technology to sensor manufacturers for delivery with its sensor hardware. This resulted in growth in 2014 revenue. 

BIO-key International, Inc. (BKYI), closed Wednesday's trading session at $0.1099, down 0.09%, on 25,100 volume with 7 trades. The average volume for the last 60 days is 98,306 and the stock's 52-week low/high is $0.07/$0.297.

Integrated Environmental Technologies Ltd. (IEVM)

Momentum Traders, HotStockChat, SmallCapVoice, Stock Guru, and OTC Picks reported previously on Integrated Environmental Technologies Ltd. (IEVM), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Integrated Environmental Technologies Ltd. operates through its wholly-owned operating subsidiary, I.E.T., Inc.  I.E.T is a manufacturing enterprise that designs and builds equipment, which incorporates innovative technologies focusing on the enhancement of the environment and the health, safety, and wellbeing of current and future generations. I.E.T. produces products that have been tested, proven, and accepted by private, state, and federal agencies. Integrated Environmental Technologies is based in Little River, South Carolina.

All of Integrated Environmental Technologies’ products and services are marketed and sold under the umbrella brand name, EcoTreatments™. Its I.E.T. subsidiary has approval by the US Food and Drug Administration (FDA) for applications of the Company’s proprietary extraction technology that is being introduced into the healthcare, medical, nutraceutical, and pharmaceutical markets.

I.E.T. sells anolyte disinfecting solution under the EcaFlo™ and Excelyte® brand names. The EcaFlo™ Division designs, manufactures, markets, sells, and installs proprietary Electro-Chemical Activation (ECA) equipment in the U.S. and globally. The unique design of EcaFlo™ equipment is to produce EcaFlo™ Anolyte and Catholyte solutions with predictable and carefully controlled properties. The EcaFlo™ equipment employs an electrolytic process called electrochemical activation to reliably produce environmentally responsible solutions for cleaning, sanitizing, and disinfecting.

EcaFlo™ Anolyte and Excelyte® solutions are Environmental Protection Agency (EPA)-registered hard surface disinfectants and sanitizers. They have approval for hospital-level use and approval for use as a biocide in oil and gas drilling. EcaFlo™ equipment uses a proprietary operating system. This system has a simple touch screen interface to control the unit's PLC and internal components.

The Company also sells a cleaning solution under the Catholyte Zero™ brand name. Catholyte Zero™ solutions are an environmentally friendly cleanser and degreaser for janitorial, sanitation, and food processing uses. Integrated Environmental Technologies announced last year that it received approval from the EPA to market a new Excelyte™ product called Excelyte VET, which can be used to prevent Canine distemper.

Integrated Environmental Technologies reported in January 2014 that it identified the oil and gas market as a market of significant potential. Concerning healthcare, it also reported that a second major market lies in the disinfection of hospitals, nursing homes, and clinics.

This past November, Integrated Environmental Technologies announced that it established a production facility in Artesia, New Mexico. It also announced that it provided Excelyte™ well maintenance treatments on four oil wells for a new customer in the northwestern area of the Permian Basin. This customer has roughly 800 oil producing wells that the Company has targeted for Excelyte well maintenance treatments. Furthermore, Integrated Environmental Technologies is also now providing Excelyte well maintenance treatments on twenty oil producing wells in the Uinta Basin in Utah for one customer and has begun treatment on two oil producing wells for a second customer.   

Integrated Environmental Technologies Ltd. (IEVM), closed Wednesday's trading session at $0.0639, down 3.18%, on 66,520 volume with 5 trades. The average volume for the last 60 days is 108,848 and the stock's 52-week low/high is $0.048/$0.1175.

Xenonics Holdings, Inc. (XNNH)

PennyStocks24, Bull Trends, Club Penny Stocks Network, PennyStockScholar, Stock Rich, Cool PennyStocks, BullRally, and Stockpalooza reported on Xenonics Holdings, Inc. (XNNH), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed Xenonics Holdings, Inc. develops and produces advanced, lightweight and compact ultra-high-intensity illumination and low-light vision products. These products are for military, law enforcement, public safety, as well as commercial and private sector applications. The Company utilizes patented technologies. Xenonics provides innovative solutions for customers who must see farther so they can do their jobs better and safer. Xenonics Holdings has its corporate head office in Carlsbad, California.

The Company’s illumination engine delivers tightly focused, ultra-high intensity beams of visible or infrared light (and also ultraviolet). Furthermore, its technology produces a beam without the "black hole" that is characteristic of other illumination products.

Xenonics' NightHunter line of illumination products is used by every branch of the U.S. Armed Forces. This line is also used by law enforcement and security agencies. NightHunters provide unique capabilities, which permit users to see first and act first, with the versatility to rapidly adapt to and dominate changing conditions at night. The NightHunter line of products consists of the NightHunter, NightHunterII, and the NightHunter EXT.

The design of Xenonics’ SuperVision high-definition night vision is for commercial and military applications. SuperVision’s performance compares to military-grade (Gen III) night vision. It provides greater resolution, better clarity, and longer range and zoom capability. SuperVision’s patented digital technology offers a 2x to 8x zoom magnification, high resolution HDTV display, as well as proprietary DSP technology. SuperVision is especially designed for military, law enforcement, and security professionals and their special requirements in the dangerous global environment. 

In November 2014, Xenonics Holdings announced that it was awarded a purchase order valued in excess of $300,000 for its NightHunter high-intensity illumination devices. The order was received from Aardvark Tactical, Inc. (ATI), Azusa, California, on behalf of the U.S. Marine Corps.

Chairman, Mr. Alan Magerman, said in November, "This order is in addition to the $200,000 in orders we received from Aardvark last month. We expect significant orders from military and international customers in the weeks and months ahead."

Xenonics Holdings, Inc. (XNNH), closed Wednesday's trading session at $0.47, up 5.88%, on 39,870 volume with 16 trades. The average volume for the last 60 days is 35,673 and the stock's 52-week low/high is $0.055/$0.445.

Marina Biotech, Inc. (MRNA)

SmarTrend Newsletters and SmallCapVoice reported previously on Marina Biotech, Inc. (MRNA), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Marina Biotech, Inc. is a leading nucleic acid-based drug discovery and development company concentrating on rare diseases. In essence, the Bothell, Washington based Company is an oligonucleotide therapeutics enterprise with extensive drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics. These include siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. 

The Company’s technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics to modulate (up or down) a specific protein(s), which is either being produced too much or too little thus causing a particular disease. Marina Biotech believes its technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases.

Furthermore, Marina Biotech believes it is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, by way of licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively.

Marina Biotech’s novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, Monsanto, and Tekmira. At present, the Marina Biotech pipeline includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy.

The Company is advancing CEQ508, for which it has received Food and Drug Administration (FDA) orphan drug designation, in a Phase 1 clinical program for patients with Familial Adenomatous Polyposis. It is expanding its rare disease focus to include myotonic dystrophy and Duchenne’s muscular dystrophy.

Marina Biotech announced in September 2014 that it received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering delivery technologies: SMARTICLES® in Europe; TransKingdom RNA™ interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. Marina Biotech has over 100 issued or allowed patents and more than 90 pending U.S. and foreign patent applications.

In December, Marina Biotech reported that its licensee, ProNAi Therapeutics, reported that several patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi®-based therapeutic, PNT2258, achieved meaningful therapeutic outcomes. They continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES® delivery technology.

Additionally, last month, Marina Biotech and MiNA Therapeutics Limited announced that they entered into a license agreement pertaining to the development and commercialization of small activating RNA (saRNA) based therapeutics using MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement. Marina Biotech will support pre-clinical and process development efforts. MiNA Therapeutics is the pioneer in RNA activation therapeutics.

Marina Biotech, Inc. (MRNA), closed Wednesday's trading session at $0.71, up 12.70%, on 338,351 volume with 145 trades. The average volume for the last 60 days is 106,625 and the stock's 52-week low/high is $0.48/$1.81.

Emisphere Technologies, Inc. (EMIS)

PennyStockRumors.net, AddictivePennyStocks, PennyStocks24, and FeedBlitz reported earlier on Emisphere Technologies, Inc. (EMIS), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Emisphere Technologies, Inc. is a specialty pharmaceutical company with corporate headquarters in Roseland, New Jersey. Emisphere has been transformed recently from a delivery systems development company into a broader commercial-stage entity. It is focusing on its first commercial product, oral Eligen® B12. The Company is preparing to launch commercial operations.  Emisphere Technologies lists on the OTC Bulletin Board.

Currently, Emisphere is preparing to launch its first prescription product, oral Eligen®B12, in the U.S. Further to Eligen®B12, the Company employs its proprietary Eligen® Technology to create new oral formulations of therapeutic agents. Its pipeline includes product candidates that have reached clinical development and an assortment of preclinical research and development programs. Emisphere is carrying out these programs in collaboration with pharmaceutical and biotechnology companies, as well as independently.

Emisphere Technologies’ Oral Eligen® B12 meets significant unmet patient and medical needs through combining B12 with Emisphere’s proprietary delivery system technology. Through building on the oral Eligen® B12 product, the Company’s intention is to establish a sound product portfolio platform on which to expand its B12 therapeutic franchise and expand internal new product development with new therapeutic agents.

Emisphere will also continue to develop its existing drug delivery carrier partnerships and expand its carrier business through looking for and engaging in new global licensing opportunities. Its strategy is to reemphasize the commercialization of Eligen® Oral B12, build new high-value partnerships, evaluate new commercial opportunities, and promote new uses for the Eligen® Technology.

The Company has developed an oral formulation of Eligen® B12 (1000 mcg) for use by B12 deficient individuals. It is covered by patent protection in the United States through approximately 2029.

Novo Nordisk is using Emisphere's Eligen® Technology to develop oral formulations of Novo Nordisk's insulin and GLP-1 receptor agonists. Novo Nordisk announced in December 2013 that it initiated its first Phase II clinical trial with a long-acting oral GLP-1 analog. Emisphere Technologies is continuing to pursue several pre-clinical programs in collaboration with other companies, as well as projects on its own, using its proprietary Eligen® Technology to improve the oral absorption of selected molecules.

Emisphere Technologies continues to emphasize the commercialization of oral Eligen®) B12, seek new high-value partnerships, evaluate new prescription Medical Foods commercial opportunities, reprioritize the product pipeline, and promote new uses for the Eligen® Technology. All key oral Eligen® B12 launch initiatives are in progress. This product is on schedule to be introduced in the United States during this first quarter of 2015. 

Emisphere Technologies, Inc. (EMIS), closed Wednesday's trading session at $0.36, down 5.26%, on 18,070 volume with 14 trades. The average volume for the last 60 days is 37,083 and the stock's 52-week low/high is $0.15/$0.46.

Alkame Holdings, Inc. (ALKM)

PennyStockScholar, OTCtipReporter, SmallCapInvestorDaily, EpicVIP Group, PennyStocks24, Gryphon Digest, Stock Tips, and Penny Stock reported earlier on Alkame Holdings, Inc. (ALKM), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Alkame Holdings, Inc. is a health and technology holding company based in Las Vegas, Nevada. Its focus is on patentable, innovative, and eco-friendly consumer products. Alkame® Water, Inc. is a wholly owned subsidiary of Alkame Holdings. The Company previously went by the name Pinacle Enterprise, Inc. It changed its corporate name to Alkame Holdings, Inc. in January of 2014. Alkame Holdings’ shares trade on the OTCQB.

Alkame® Water is a technology and health company. It distributes bottled water with a patented technology and patented formula, which alters the molecular structure of water. Alkame® Water’s patented technology restructures the water allowing for ultra-hydration. Its patented technology makes water with many unique properties. These properties enable the body to absorb and use it more efficiently and help to attain an optimal pH balance.

The Company says that the patented Alkame technology increases the available oxygen content and absorbability. This equates to more fuel for improved metabolic efficiency, boosted immune system, and also improved cardio respiratory function.

Alkame® Water markets and distributes micro-clustered, alkaline, antioxidant, and oxygenated bottled water. Alkame® holds distributorship rights to market and sell bottled water in the U.S., Mexico, and Canada.

In April 2014, Alkame Holdings announced the launch of 20 oz. and one US gallon sizes of Alkame™ bottled water. Alkame's bottled water is now available in a 16.9oz (half liter), 20oz., 33.8oz (1 liter), two Premium gallon configurations, and a 1.5 liter is scheduled to be added this year. These utilize exclusive BPA-free and 100 percent recyclable eco-friendly plastics from BioSphere Plastic of Portland, Oregon. The Company has added a 100 percent Fluoride-Free Premium Drinking Water for infants and children to its premium bottled water lineup.

Alkame Holdings announced recently its entry into the aquaculture sector with the acquisition of High Country Shrimp Company (HCS). HCS is a Colorado-based indoor aquaculture technology developer and operations enterprise. Alkame also expects closing of an acquisition with Xtreme Technology, another privately held company. Alkame notes that it anticipates that with its continuing development of Alkame in the Aqua Culture sector, it should see an even greater increase in demand once the Xtreme acquisition is consummated. 

Last week, Alkame Holdings provided an update of comments from its Chief Executive Officer, Mr. Robert Eakle, pertaining to its recent business progress. Part of his comments included Mr. Eakle stating that, "During the past year, we secured Avanzar, our very first distributor, and have since established relationships with many of the key distribution networks that now puts us in a position to penetrate additional market coverage in select markets across the US with groups that include UNFI, Natures Best, River Valley/Cavallero, Natural Wayz, Charm City, and Senuca. We look forward to announcing the addition of more new distributors in early 2015."

Alkame Holdings, Inc. (ALKM), closed Wednesday's trading session at $0.04, even for the day, on 339,327 volume with 26 trades. The average volume for the last 60 days is 1,342,996 and the stock's 52-week low/high is $0.03/$0.54.

graphic

The QualityStocks
Company Corner

graphic
graphic

IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.89, up 16.34%, on 2,248,107 volume with 890 trades. The stock’s average daily volume over the past 60 days is 568,800, and its 52-week low/high is $0.0114/$0.89.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial Enters Agreement to Provide Development Assistance to Card Collaborative International, LLC

IFAN Financial Announces $1 Million Private Placement

IFAN Financial Reaches Technology Development Milestones, Receives Approval From Apple and Google

MIT Holding (MITD)

The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.0451, up 0.22%, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 43,352, and its 52-week low/high is $0.04/$0.31.

MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.

In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.

Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.

MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer

MIT Holding Company Blog

MIT Holding News:

MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services

MIT Holding, Inc. (MITD) Announces Profitable 3rd Quarter Financial Results

MIT Holding, Inc. (MITD) Announces Initial Revenue Generation From “Melinta AB sssi” FDA Trial

Pure Hospitality Solutions, Inc. (PNOW)

The QualityStocks Daily Newsletter would like to spotlight Pure Hospitality Solutions, Inc. (PNOW). Today, Pure Hospitality Solutions, Inc. closed trading at $0.04, even for the day, on 100,165 volume with 21 trades. The stock’s average daily volume over the past 60 days is 35,601, and its 52-week low/high is $0.0031/$0.9412.

Pure Hospitality Solutions, Inc. (PNOW) is a provider of proprietary technology, marketing solutions, infrastructure and branding services to hotel operators.

The company's innovative platform functions as a powerful vehicle to help hotel operators achieve greater success in three specific areas: (i) expanded international exposure and recognition, (ii) powerful core structure, and (iii) high occupancy rates that drive increases in bottom-line profits. Pure continuously refines its suite of proprietary solutions to deliver measurable and proven results to hotel properties. This success has been reflected in those properties operating under the Hotel PURE brand as well as with independent boutique hotel properties utilizing the company's Friendly Reservation Online (FROL) booking engine technology and internet marketing services.

Operating a successful bi-lateral business model, Pure has four objectives:

1. To franchise the Hotel PURE brand to selected hotel properties worldwide similar to the business model currently employed by Big Brand operators such as Holiday Inn, Marriott, Sheraton and others;

2. Provide highly efficient and economical back-end booking engine technology services to independently branded boutique hotels that require a robust online presence;

3. Launch a stand-alone online hotel booking search engine primarily focused on Central America; and,

4. Expand the portfolio of Pure-owned boutique hotels operating under the Hotel PURE brand.

The company initially began growing its operations primarily in the United States. However most recently, major opportunities in Central America began presenting themselves, giving Oriens the ability to retool its business model. Now the company is positioned to acquire, own and operate its own properties – which would be marketed under the new brand with occupancies handled by the re-launched online booking engine system.

Ultimately, Pure intends to become a top-tier hotel brand operator and Internet booking and marketing service provider, qualifying as a preferred supplier to lending institutions. The company also intends to establish an invaluable international footprint with its online booking engine technology and marketing offerings; making that segment of its business a prime acquisition target for major online travel search and booking engine companies. Advancement toward this goal is guided by an executive management team with deep expertise in technology, banking, management, hospitality, branding and marketing, technical development and more. Disclaimer

Pure Hospitality Solutions, Inc. Company Blog

Pure Hospitality Solutions, Inc. News:

PURE Hospitality Solutions Releases FROL Case Study; Establishing Viability of Central American-Caribbean Launch of Oveedia

PURE Hospitality Solutions Announces NEW Online Hotel Booking Engine; OVEEDIA

PURE Hospitality Solutions Discusses 2015 Initiatives

WRIT Media Group, Inc. (WRIT)

The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.005, even for the day, on 3 volume with 1 trade. The stock’s average daily volume over the past 60 days is 70,308, and its 52-week low/high is $0.005/$0.50.

WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer

WRIT Media Group, Inc. Company Blog

WRIT Media Group, Inc. News:

WRIT Media Group Announces Product Updates and NASCAR Event Recap

Retro Infinity Sponsors NASCAR Driver Carlos Contreras' Record-Breaking 99th Career Race

WRIT Media Group (WRIT) CEO Featured in Exclusive QualityStocks Interview

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.017, even for the day. The stock’s average daily volume over the past 60 days is 11,171, and its 52-week low/high is $0.0066/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Panther Energy Changes Name to Falcon Crest Energy

Technology Applications International, Inc. (NUUU)

The QualityStocks Daily Newsletter would like to spotlight Technology Applications International, Inc. (NUUU). Today, Technology Applications International, Inc. closed trading at $0.4798, off by 5.90%, on 1,606 volume with 5 trades. The stock’s average daily volume over the past 60 days is 3,713, and its 52-week low/high is $0.10/$4.50.

Technology Applications International, Inc. (NUUU) is focused on producing, distributing, marketing and selling skincare products, in addition to engaging in the environmental management and water purification industries. The company conducts its business through two separate wholly owned subsidiaries: Rejuvel Int'l, Inc. and NueEarth, Inc.

Rejuvel Int'l, Inc. developed its skincare line of products using a NASA bioreactor to grow and expand three-dimensional fibroblast cells. Using exclusively licensed technology, licensed from the National Aeronautics and Space Administration and Administrators of the Tulane Educational Fund under U.S. Patent No. 6,730,498, the Rejuvel’s flagship anti-aging facial products trigger the multiplication of human fibroblast skin cells that rebuild skin for a firm, healthy and youthful appearance. The company has been awarded a “seal of approval” from the Space Certification program, setting a new standard for innovation in an industry projected to reach $114 billion in sales by 2015.

NueEarth, Inc. provides environmental management solutions and water purification techniques using a mobile electron beam accelerator unit which creates high-energy electrons that produce free radicals in the wastewater to decompose organic compounds or pollutants. The company has identified a number of different markets for this particle accelerator technology, including the removal of pollutants from wastewater, drinking water, municipal sludge and water that’s contaminated by the fracking process.

Technology Applications International’s management team is methodically establishing its brand in the marketplace with well-respected associations and strategic marketing initiatives. As the company continues to pursue direct consumer sales and other opportunities, it stands to do well with the foundation management has laid for growth. Disclaimer

Technology Applications International, Inc. Company Blog

Technology Applications International, Inc. News:

Rejuvel Int'l, Inc. Will Have its Products Included in Celebrity Gift Bags at the 15th Annual Latin GRAMMY® Awards Show at the MGM Grand in Las Vegas

Rejuvel Int'l, Inc., a Wholly Owned Subsidiary of NUUU, Announced Today the Signing of a Distribution Agreement with Meditem Cyprus Limited

Rejuvel Int'l, Inc., a Wholly Owned Subsidiary of NUUU, Expands its International Branding Efforts with Placements of Multiple Full Page Print Advertisements in International Fashion and Health Magazines

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $8.00, even for the day. The stock’s average daily volume over the past 60 days is 232, and its 52-week low/high is $5.508/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

SmallCapFinancialWire
(NTFU)

2.

OTCtipReporter
(PAOC)

3.

FatCat Stocks
(PEFF)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251